In this Issue:
Adding rituximab to CEOP improves outcomes in non-GCB DLBCL
Cladribine for treating HCL in young patients
Brentuximab vedotin + ABVD/AVD for newly diagnosed HL
FDG-avid lymph nodes after allogeneic, not autologous, SCT in lymphoma
Increased BMI associated with improved OS in DLBCL
p-AKT expression and DLBCL clinical outcomes
Prognostic significance of whole-body MRI in MGUS
Mobilising CD34+ cells with BKT140 in MM
Breast implant-associated ALCL
Please login below to download this issue (PDF)